LifeArc
6
2
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II
Role: collaborator
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
Role: collaborator
Telehealth in MND-Research (TIM-R): A Research Database for MND
Role: collaborator
ANNE Sensor Monitoring in Cystic Fibrosis
Role: collaborator
Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
Role: collaborator
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
Role: collaborator
All 6 trials loaded